We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Adare Pharmaceuticals and Teva Pharmaceuticals International have sued Apotex, alleging its generic version of Amrix infringes on a patent covering the dosage forms of the drug’s active ingredient. Read More
In a Phase III trial, Janssen’s injectable plaque psoriasis treatment delivered better head-to-head clinical results than international top-selling drug Humira, which amassed over $14 billion in sales in 2015. Read More
Par Pharmaceuticals has sued the FDA for not granting the company 180 days of marketing exclusivity for its first generic of Takeda Pharmaceutical’s Colcrys, asking a federal court to enjoin the agency from approving any competing generics. Read More
Repatha demonstrated positive effects on plaque buildup in coronary artery disease in patients already treated with optimized statin therapy. Read More
A federal appellate court upheld a district court dismissal of Mylan’s antitrust case against Warner Chilcott and Mayne Pharmaceuticals, which alleged that the name-brand drugmakers modified their acne treatment Doryx to maintain a monopoly on the market. Read More
The EMA is appealing a temporary injunction from the General Court of the European Union that prevents the agency from releasing a clinical study report on PTC Therapeutics’ Duchenne muscular dystrophy drug Translarna. Read More